The corporate structure of Inovio is well thought out and is a balance of physicians, scientists and corporate developers. All with good experience. The one person that appears to be among the missing is an inhouse regulatory affairs person. I think they will hire this person if the go independent. Otherwise they will rely on the regulatory capabilities of their collaborators. The nice thing about vaccines is that if they produce the antibody, which is measurable in the blood, secretion or other biological liquid, they are half way to demonstrating their endpoints. Then it bacomes whether or not the antibody elicited is protective or therapeutic.